A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

Int J Cancer · 2016 · PMC5071720 · PMID 26891420

Europe PMC DOI

hedged sentences

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

a nonsignificant trendP = 0.15not close (p > 0.1)

Overall survival There was a nonsignificant trend toward improved OS in the tivantinib group (19.8 months; 95% CI, 13.4–27.0) compared with the placebo group (16.9 months; 95% CI, 12.2–20.4; HR, 0.70; P = 0.15) (Fig. 2 b ).

also in 5,406 other papers

did not reach statistical significanceno p-value reported

Consequently, the estimated 30% reduction in risk of death with addition of tivantinib did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.